The innovative pharmaceutical industry is ushering in a window of intensive expansion of new indications. Domestic pharmaceutical companies have successively approved a number of innovative drugs for new indications, and some major global drugs have also continued to break through the application boundaries of original diseases. “One drug expands multiple domains” is becoming a common development strategy adopted at home and abroad. Innovative drugs with a single indication can easily reach the sales ceiling after they are marketed. However, some varieties that have the potential to continuously expand indications can prolong product life cycles, dilute R&D and commercialization costs, and are also expected to reshape the growth logic of innovative drug pipelines.

The innovative pharmaceutical industry is ushering in a window of intensive expansion of new indications. Domestic pharmaceutical companies have successively approved a number of innovative drugs for new indications, and some major global drugs have also continued to break through the application boundaries of original diseases. “One drug expands multiple domains” is becoming a common development strategy adopted at home and abroad. Innovative drugs with a single indication can easily reach the sales ceiling after they are marketed. However, some varieties that have the potential to continuously expand indications can prolong product life cycles, dilute R&D and commercialization costs, and are also expected to reshape the growth logic of innovative drug pipelines.